Felbamate: A new evaluation in refractory epileptic patients

L. M. Specchio, A. La Neve, A. Spinelli, G. Boero, N. Specchio

Research output: Contribution to journalArticle

Abstract

Felbamate (FBM) is marketed for the treatment of Lennox-Gastaut syndrome. Many reports referred the efficacy in partial epilepsy. FBM add-on treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy. 4 Lennox-Gastaut syndrome) in an open-label trial. FBM was titrated up to the satisfactory clinical control or the maximal tolerated dose, not exceeding 3600 mg/day (3064 ±834). Blood parameters of liver and bone marrow functions were checked at recruitment and every fortnight after FBM was added. A >509l increase of serum values of transaminases and/or alkaline phosphatase. and/or a reduction 2000) of white cells caused the FBM withdrawal. The primary efficacy variables were the mean monthly seizure frequency calculated on a three-month basis and compared versus baseline, and the number of seizure-free patients. Thirty-two patients with at least 3-month follow-up have been included in the efficacy evaluation. No change in mean seizure frequency vs. baseline was found in partial as well as generalized seizures: 6 patients showed a seizure reduction greater than S09i and 2 were seizure-free over a period ranging 12 to 24 months. All patients have been included in the tolerability analysis. Ten dropped-out in the first quarter (8 because of adverse effects, 2 for personal reasons). In 3 cases an increase of serum transaminases and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found. Twenty-seven patients experienced side effects: drowsiness (20.4'/r ). stomach ache (14.2%), and weight loss >5% (9.59l ) were the most frequent side effects. The FBM in this open-label long-term study performed in severe refractory epilepsies showed efficacy in a wide range of seizures. Monitoring liver and bone marrow functions permits a sufficient safety.

Original languageEnglish
Pages (from-to)357
Number of pages1
JournalItalian Journal of Neurological Sciences
Volume20
Issue number5
Publication statusPublished - 1999

Fingerprint

felbamate
Seizures
Partial Epilepsy
Transaminases
Alkaline Phosphatase
Epilepsy
Bone Marrow
Maximum Tolerated Dose
Sleep Stages
Liver
Serum
Weight Loss
Stomach

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Specchio, L. M., La Neve, A., Spinelli, A., Boero, G., & Specchio, N. (1999). Felbamate: A new evaluation in refractory epileptic patients. Italian Journal of Neurological Sciences, 20(5), 357.

Felbamate : A new evaluation in refractory epileptic patients. / Specchio, L. M.; La Neve, A.; Spinelli, A.; Boero, G.; Specchio, N.

In: Italian Journal of Neurological Sciences, Vol. 20, No. 5, 1999, p. 357.

Research output: Contribution to journalArticle

Specchio, LM, La Neve, A, Spinelli, A, Boero, G & Specchio, N 1999, 'Felbamate: A new evaluation in refractory epileptic patients', Italian Journal of Neurological Sciences, vol. 20, no. 5, pp. 357.
Specchio, L. M. ; La Neve, A. ; Spinelli, A. ; Boero, G. ; Specchio, N. / Felbamate : A new evaluation in refractory epileptic patients. In: Italian Journal of Neurological Sciences. 1999 ; Vol. 20, No. 5. pp. 357.
@article{aa85d63317db4035a5d87eb14e14b5b4,
title = "Felbamate: A new evaluation in refractory epileptic patients",
abstract = "Felbamate (FBM) is marketed for the treatment of Lennox-Gastaut syndrome. Many reports referred the efficacy in partial epilepsy. FBM add-on treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy. 4 Lennox-Gastaut syndrome) in an open-label trial. FBM was titrated up to the satisfactory clinical control or the maximal tolerated dose, not exceeding 3600 mg/day (3064 ±834). Blood parameters of liver and bone marrow functions were checked at recruitment and every fortnight after FBM was added. A >509l increase of serum values of transaminases and/or alkaline phosphatase. and/or a reduction 2000) of white cells caused the FBM withdrawal. The primary efficacy variables were the mean monthly seizure frequency calculated on a three-month basis and compared versus baseline, and the number of seizure-free patients. Thirty-two patients with at least 3-month follow-up have been included in the efficacy evaluation. No change in mean seizure frequency vs. baseline was found in partial as well as generalized seizures: 6 patients showed a seizure reduction greater than S09i and 2 were seizure-free over a period ranging 12 to 24 months. All patients have been included in the tolerability analysis. Ten dropped-out in the first quarter (8 because of adverse effects, 2 for personal reasons). In 3 cases an increase of serum transaminases and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found. Twenty-seven patients experienced side effects: drowsiness (20.4'/r ). stomach ache (14.2{\%}), and weight loss >5{\%} (9.59l ) were the most frequent side effects. The FBM in this open-label long-term study performed in severe refractory epilepsies showed efficacy in a wide range of seizures. Monitoring liver and bone marrow functions permits a sufficient safety.",
author = "Specchio, {L. M.} and {La Neve}, A. and A. Spinelli and G. Boero and N. Specchio",
year = "1999",
language = "English",
volume = "20",
pages = "357",
journal = "Italian Journal of Neurological Sciences",
issn = "0392-0461",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Felbamate

T2 - A new evaluation in refractory epileptic patients

AU - Specchio, L. M.

AU - La Neve, A.

AU - Spinelli, A.

AU - Boero, G.

AU - Specchio, N.

PY - 1999

Y1 - 1999

N2 - Felbamate (FBM) is marketed for the treatment of Lennox-Gastaut syndrome. Many reports referred the efficacy in partial epilepsy. FBM add-on treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy. 4 Lennox-Gastaut syndrome) in an open-label trial. FBM was titrated up to the satisfactory clinical control or the maximal tolerated dose, not exceeding 3600 mg/day (3064 ±834). Blood parameters of liver and bone marrow functions were checked at recruitment and every fortnight after FBM was added. A >509l increase of serum values of transaminases and/or alkaline phosphatase. and/or a reduction 2000) of white cells caused the FBM withdrawal. The primary efficacy variables were the mean monthly seizure frequency calculated on a three-month basis and compared versus baseline, and the number of seizure-free patients. Thirty-two patients with at least 3-month follow-up have been included in the efficacy evaluation. No change in mean seizure frequency vs. baseline was found in partial as well as generalized seizures: 6 patients showed a seizure reduction greater than S09i and 2 were seizure-free over a period ranging 12 to 24 months. All patients have been included in the tolerability analysis. Ten dropped-out in the first quarter (8 because of adverse effects, 2 for personal reasons). In 3 cases an increase of serum transaminases and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found. Twenty-seven patients experienced side effects: drowsiness (20.4'/r ). stomach ache (14.2%), and weight loss >5% (9.59l ) were the most frequent side effects. The FBM in this open-label long-term study performed in severe refractory epilepsies showed efficacy in a wide range of seizures. Monitoring liver and bone marrow functions permits a sufficient safety.

AB - Felbamate (FBM) is marketed for the treatment of Lennox-Gastaut syndrome. Many reports referred the efficacy in partial epilepsy. FBM add-on treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy. 4 Lennox-Gastaut syndrome) in an open-label trial. FBM was titrated up to the satisfactory clinical control or the maximal tolerated dose, not exceeding 3600 mg/day (3064 ±834). Blood parameters of liver and bone marrow functions were checked at recruitment and every fortnight after FBM was added. A >509l increase of serum values of transaminases and/or alkaline phosphatase. and/or a reduction 2000) of white cells caused the FBM withdrawal. The primary efficacy variables were the mean monthly seizure frequency calculated on a three-month basis and compared versus baseline, and the number of seizure-free patients. Thirty-two patients with at least 3-month follow-up have been included in the efficacy evaluation. No change in mean seizure frequency vs. baseline was found in partial as well as generalized seizures: 6 patients showed a seizure reduction greater than S09i and 2 were seizure-free over a period ranging 12 to 24 months. All patients have been included in the tolerability analysis. Ten dropped-out in the first quarter (8 because of adverse effects, 2 for personal reasons). In 3 cases an increase of serum transaminases and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found. Twenty-seven patients experienced side effects: drowsiness (20.4'/r ). stomach ache (14.2%), and weight loss >5% (9.59l ) were the most frequent side effects. The FBM in this open-label long-term study performed in severe refractory epilepsies showed efficacy in a wide range of seizures. Monitoring liver and bone marrow functions permits a sufficient safety.

UR - http://www.scopus.com/inward/record.url?scp=33746324260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746324260&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746324260

VL - 20

SP - 357

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 5

ER -